You are here

  • Home
  • Archive
  • Volume 6, Issue Suppl 1
  • OP18 A systematic review and meta-analysis of tourniquet use during major lower limb amputation for complications of peripheral arterial disease

Article Text

Article menu

Download PDFPDF

Oral Presentations
Sandpit Presentations
OP18 A systematic review and meta-analysis of tourniquet use during major lower limb amputation for complications of peripheral arterial disease
  1. Jessie Shea1,
  2. Elisabeth Smith2,
  3. Megan Lyons3,
  4. Monty Fricker3,
  5. R Laloo4 and
  6. David Bosanquet2
  1. 1Kingston Hospital, Kingston Hospital NHS Foundation Trust, UK
  2. 2South East Wales Vascular Network, Royal Gwent Hospital, Aneurin Bevan University Health Board, UK
  3. 3Section of Vascular Surgery, Department of Surgery and Cancer, Imperial College London, UK
  4. 4Leeds Vascular Institute, Leeds General Infirmary, Leeds, UK

Abstract

Objective Intraoperative blood loss is a significant complication of major lower limb amputation (MLLA). However, tourniquet use in peripheral arterial disease (PAD) remains contentious. This meta-analysis assessed the effect of tourniquet use on PAD patient outcomes following MLLA.

Methods EMBASE, Medline and Cochrane were searched. Inclusion criteria were any study design reporting outcomes of MLLA for PAD with and without tourniquet use. Papers were pooled using random effects meta-analysis.

Results Six studies were included, totalling 921 patients. Postoperative Hb drop was significantly reduced for tourniquet patients (MD -0.55; 95%CI -0.80 to -0.31; P<0.0001). OR for requiring blood transfusion was 0.58 (95%CI 0.31 to 1.10; P=0.10) in the tourniquet versus non-tourniquet groups, whilst number of units transfused per patient were lower (MD -0.35; 95%CI -0.74 to 0.04; P=0.08). Operation length was significantly reduced in tourniquet patients (MD -8.69; 95%CI -15.95 to -1.42; P=0.02). There was no significant difference in surgical site infection (SSI) (OR 1.07; 95%CI 0.60 to 1.90; P=0.82), stump revision (SR) (OR 0.73; 95%CI 0.41 to 1.30; P=0.29), and death (OR 0.80; 95%CI 0.49 to 1.30; P=0.36) in the tourniquet versus non-tourniquet cohort.

Conclusions Tourniquet use during MLLA significantly reduces blood loss and operative duration, with no significant difference in SSI, SR and mortality. Further RCTs are needed to generate higher quality evidence which may change practice.

http://creativecommons.org/licenses/by-nc/4.0/

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

https://doi.org/10.1136/bmjsit-2024-IDEAL.16

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.